The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea

Brain

Volumn 130, Issue 1, 2007, Pages 222-232

  Huot, Philippe ^a,b   Lévesque, Martin ^a   Parent, André ^a,c  

^a UNIVERSITY OF QUEBEC   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

Basal ganglia; Dopamine; Neurodegenerative diseases; Striatal neurons; Striatum

Indexed keywords

ANTIBODY; DOPAMINE; LEVODOPA; TYROSINE 3 MONOOXYGENASE;

ADULT; AGED; ARTICLE; AUTOPSY; CAUDATE NUCLEUS; CELL STRUCTURE; CELL SUBPOPULATION; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITE; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INTERNEURON; MALE; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; STEREOLOGY;

EID: 33845870145     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl332     Document Type: Article

References (70)

1. Baker H, Kobayashi K, Okano H, Saino-Saito S. Cortical and striatal expression of tyrosine hydroxylase mRNA in neonatal and adult mice. Cell Mol Neurobiol 2003; 23: 507-18.
2. Bédard A, Cossette M, Lévesque M, Parent A. Proliferating cells can differentiate into neurons in the striatum of normal adult monkey. Neurosci Lett 2002; 328: 213-6.
3. Betarbet R, Greenamyre JT. Differential expression of glutamate receptors by the dopaminergic neurons of the primate striatum. Exp Neurol 1999; 159: 401-8.
4. Betarbet R, Turner R, Chockkan V, DeLong MR, Allers KA, Walters J, et al. Dopaminergic neurons intrinsic to the primate striatum. J Neurosci 1997; 17: 6761-8.
5. Bezard E, Gross CE. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog Neurobiol 1998; 55: 93-116.
6. Bezard E, Gross CE, Brotchie JM. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 2003; 26: 215-21.
7. Bird ED. Chemical pathology of Huntington's disease. Annu Rev Pharmacol Toxicol 1980; 20: 533-51.
8. Bird ED, Spokes EG, Iversen LL. Dopamine and noradrenaline in postmortem brain in Huntington's disease and schizophrenic illness. Acta Psychiatr Scand Suppl 1980; 280: 63-73.
9. Carlsson A. Brain neurotransmitters in aging and dementia: similar changes across diagnostic dementia groups. Gerontology 1987; 33: 159-67.
10. Cicchetti F, Parent A. Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons. Mov Disord 1996; 11: 619-26.
11. Cicchetti F, Gould PV, Parent A. Sparing of striatal neurons coexpressing calretinin and substance P (NK1) receptors in Huntington's disease. Brain Res 1996; 730: 232-7.
12. Cicchetti F, Prensa L, Wu Y, Parent A. Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res Brain Res Rev 2000; 34: 80-101.
13. Cossette M, Lévesque M, Parent A. Extrastriatal dopaminergic innervation of human basal ganglia. Neurosci Res 1999; 34: 51-4.
14. Cossette M, Bédard A, Parent A. Dopaminergic neurons in human striatum and neurogenesis in adult monkey striatum. Ann NY Acad Sci 2003; 991: 346-9.
15. Cossette M, Parent A, Lévesque D. Tyrosine hydroxylase-positive neurons intrinsic to the human striatum express the transcription factor Nurr1. Eur J Neurosci 2004; 20: 2089-95.
16. Cossette M, Lecomte F, Parent A. Morphology and distribution of dopaminergic neurons intrinsic to the human striatum. J Chem Neuroanat 2005a; 29: 1-11.
17. Cossette M, Lévesque D, Parent A. Neurochemical characterization of dopaminergic neurons in human striatum. Parkinsonism Relat Disord 2005b; 11: 277-86.
18. Dawbarn D, De Quidt ME, Emson PC. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res 1985; 340: 251-60.
19. e Édition. Ottawa: Éditions de l'Université d'Ottawa; 1969.
20. Du X, Iacovitti L. Synergy between growth factors and transmitters required for catecholamine differentiation in brain neurons. J Neurosci 1995; 15: 5420-7.
21. Du X, Iacovitti L. Multiple signaling pathways direct the initiation of tyrosine hydroxylase gene expression in cultured brain neurons. Brain Res Mol Brain Res 1997a; 50: 1-8.
22. Du X, Iacovitti L. Protein kinase C activators work in synergy with specific growth factors to initiate tyrosine hydroxylase gene expression in striatal neurons in culture. J Neurochem 1997b; 68: 564-9.
23. Du X, Stull ND, Iacovitti L. Brain-derived neurotrophic factor works coordinately with partner molecules to initiate tyrosine hydroxylase expression in striatal neurons. Brain Res 1995; 680: 229-33.
24. Dubach M, Schmidt R, Kunkel D, Bowden DM, Martin R, German DC. Primate neostriatal neurons containing tyrosine hydroxylase: immunohistochemical evidence. Neurosci Lett 1987; 75: 205-10.
25. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamine (3-hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 1960; 38: 1236-9.
26. Ershov PV, Ugrumov MV, Calas A, Krieger M, Thibault J. Degeneration of dopaminergic neurons triggers an expression of individual enzymes of dopamine synthesis in non-dopaminergic neurons of the arcuate nucleus in adult rats. J Chem Neuroanat 2005; 30: 27-33.
27. Esiri MM, Hyman BT, Beyreuther K, Masters CL. Ageing and dementia. In: Graham DI, Lantos PL, editors. Greenfield's neuropathology. 6th edn. London: Arnold & Oxford University Press; 1997. p. 158-233.
28. Ferrante RJ, Kowall NW. Tyrosine hydroxylase-like immunoreactivity is distributed in the matrix compartment of normal human and Huntington's disease striatum. Brain Res 1987; 416: 141-6.
29. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990; 13: 244-54.
30. Hattiangady B, Rao MS, Shetty GA, Shetty AK. Brain-derived neurotrophic factor, phosphorylated cyclic AMP response element binding protein and neuropeptide Y decline as early as middle age in the dentate gyrus and CA1 and CA3 subfields of the hippocampus. Exp Neurol 2005; 195: 353-71.
31. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1986; 45: 19-34.
32. e Édition. Québec: Les Presses de l'Université Laval; 2003.
33. Hwang IK, Yoo KY, Jung BK, Cho JH, Kim DH, Kang TC, et al. Correlations between neuronal loss, decrease of memory, and decrease expression of brain-derived neurotrophic factor in the gerbil hippocampus during normal aging. Exp Neurol 2006; 201: 75-83.
34. Iacovitti L. Effects of a novel differentiation factor on the development of catecholamine traits in noncatecholamine neurons from various regions of the rat brain: studies in tissue culture. J Neurosci 1991; 11: 2403-9.
35. Ikemoto K, Satoh K, Kitahama K, Maeda T. Demonstration of a new dopamine-containing cell group in the primate rostral telencephalon. Neurosci Lett 1996; 220: 69-71.
36. Ikemoto K, Kitahama K, Jouvet A, Arai R, Nishimura A, Nishi K, et al. Demonstration of L-dopa decarboxylating neurons specific to human striatum. Neurosci Lett 1997; 232: 111-4.
37. Jiao Y, Sun Z, Lee T, Fusco FR, Kimble TD, Meade CA, et al. A simple and sensitive antigen retrieval method for free-floating and slide-mounted tissue sections. J Neurosci Methods 1999; 93: 149-62.
38. Johnston JG, Gerfen CR, Haber SN, van der Kooy D. Mechanisms of striatal pattern formation: conservation of mammalian compartmentalization. Brain Res Dev Brain Res 1990; 57: 93-102.
39. Jollivet C, Montero-Menei CN, Venier-Julienne MC, Sapin A, Benoit JP, Menei P. Striatal tyrosine hydroxylase immunoreactive neurons are induced by L-dihydroxyphenylalanine and nerve growth factor treatment in 6-hydroxydopamine lesioned rats. Neurosci Lett 2004; 362: 79-82.
40. Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 1996; 67: 443-62.
41. Lang AE, Lozano AM. Parkinson's disease (Part 2 of 2). N Engl J Med 1998; 339: 1130-43.
42. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 1975; 195: 453-64.
43. Lopez-Real A, Rodriguez-Pallares J, Guerra MJ, Labandeira-Garcia JL. Localization and functional significance of striatal neurons immunoreactive to aromatic L-amino acid decarboxylase or tyrosine hydroxylase in rat parkinsonian models. Brain Res 2003; 969: 135-46.
44. Mao L, Lau YS, Petroske E, Wang JQ. Profound astrogenesis in the striatum of adult mice following nigrostriatal dopaminergic lesion by repeated MPTP administration. Brain Res Dev Brain Res 2001; 131: 57-65.
45. Marsden CD. The mysterious motor function of the basal ganglia: The Robert Wartenberg Lecture. Neurology 1982; 32: 514-39.
46. Mazloom M, Smith Y. Synaptic microcircuitry of tyrosine hydroxylase-containing neurons and terminals in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Comp Neurol 2006; 495: 453-69.
47. Meredith GE, Farrell T, Kellaghan P, Tan Y, Zahm DS, Totterdell S. Immunocytochemical characterization of catecholaminergic neurons in the rat striatum following dopamine-depleting lesions. Eur J Neurosci 1999; 11: 3585-96.
48. Mura A, Jackson D, Manley MS, Young SJ, Groves PM. Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-dopa to dopamine. Brain Res 1995; 704: 51-60.
49. Nakahara T, Yamamoto T, Endo K, Kayama H. Neuronal ectopic expression of tyrosine hydroxylase in the mouse striatum by combined administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 3-nitropropionic acid. Neuroscience 2001; 108: 601-10.
50. Ockleford CD, Hsi BL, Wakely J, Badley RA, Whyte A, Faulk WP. Propidium iodide as a nuclear marker in immunofluorescence I. Use with tissue and cytoskeleton studies. J Immunol Methods 1981; 43: 261-7.
51. Palfi S, Leventhal L, Chu Y, Ma SY, Emborg M, Bakay R, et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 2002; 22: 4942-54.
52. Parent A, editor. Carpenter's human neuroanatomy. 9th edn. Baltimore: Williams & Wilkins; 1996.
53. Parent A, Hazrati LN. Functional anatomy of the basal ganglia I. The corticobasal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 1995; 20: 91-127.
54. Parent A, Côté PY, Lavoie B. Chemical anatomy of primate basal ganglia. Prog Neurobiol 1995; 46: 131-97.
55. Petersén Å, Mani K, Brundin P. Recent advances on the pathogenesis of Huntington's disease. Exp Neurol 1999; 157: 1-18.
56. Porritt MJ, Batchelor PE, Hughes AJ, Kalnins R, Donnan GA, Howells DW. New dopaminergic neurons in Parkinson's disease striatum. Lancet 2000; 356: 44-5.
57. Prensa L, Parent A. The nigrostriatal pathway in the rat: a single-axon study of the relationship between dorsal and ventral tier nigral neurons and the striosome/matrix striatal compartments. J Neurosci 2001; 21: 7247-60.
58. Prensa L, Giménez-Amaya JM, Parent A. Chemical heterogeneity of the striosomal compartment in the human striatum. J Comp Neurol 1999; 413: 603-18.
59. Prensa L, Cossette M, Parent A. Dopaminergic innervation of human basal ganglia. J Chem Neuroanat 2000; 20: 207-13.
60. Shannon KM. Movement disorders. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, editors. Neurology in clinical practice. 4th edn. Tome II. Philadelphia: Butterworth-Heinemann; 2004. p. 2125-68.
61. Siegel S, editor. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill; 1956.
62. Smith Y, Kieval JZ. Anatomy of the dopamine system in the basal ganglia. Trends Neurosci 2000; 23 (Suppl 10): S28-33.
63. Spokes EG. Dopamine in Huntington's disease: a study of post-mortem brain tissue. Adv Neurol 1979; 23: 481-93.
64. Spokes EG. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain 1980; 103: 179-210.
65. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's The pharmacological basis of therapeutics, 11th edn. New York: McGraw-Hill; 2006. p. 527-45.
66. Stull ND, Jung JW, Iacovitti L. Induction of a dopaminergic phenotype in cultured striatal neurons by bone morphogenic proteins. Brain Res Dev Brain Res 2001; 130: 91-8.
67. Tandé D, Höglinger G, Debeir T, Freundlieb N, Hirsch EC, François C. New striatal dopamine neurons in MPTP-treated macaques results from a phenotypic shift and not neurogenesis. Brain 2006; 129: 1194-200.
68. Tashiro Y, Sugimoto T, Hattori T, Uemura Y, Nagatsu I, Kikuchi H, et al. Tyrosine hydroxylase-like immunoreactive neurons in the striatum of the rat. Neurosci Lett 1989; 97: 6-10.
69. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-77.
70. Waring MJ. Complex formation between ethidium bromide and nucleic acids. J Mol Biol 1965; 13: 269-82.